Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of seladelpar in adults with primary sclerosing cholangitis
MOH_2019-09-24_007406Phase 2Not yet recruiting
- Sponsor
- CymaBay Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seladelpar in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by CymaBay Therapeutics. Primary endpoint: Change in alkaline phosphatase. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
seladelpar
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on MOH_2019-09-24_007406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-24_007406.